WO2018086585A8 - Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof - Google Patents

Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof Download PDF

Info

Publication number
WO2018086585A8
WO2018086585A8 PCT/CN2017/110438 CN2017110438W WO2018086585A8 WO 2018086585 A8 WO2018086585 A8 WO 2018086585A8 CN 2017110438 W CN2017110438 W CN 2017110438W WO 2018086585 A8 WO2018086585 A8 WO 2018086585A8
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen
containing heterocyclic
heterocyclic compounds
applications
preparation
Prior art date
Application number
PCT/CN2017/110438
Other languages
French (fr)
Chinese (zh)
Other versions
WO2018086585A1 (en
Inventor
胡永韩
蔡冬梅
董平
朱久香
李曼华
董加强
王铁林
Original Assignee
山东罗欣药业集团股份有限公司
罗欣生物科技（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山东罗欣药业集团股份有限公司, 罗欣生物科技（上海）有限公司 filed Critical 山东罗欣药业集团股份有限公司
Priority to CN201780067789.4A priority Critical patent/CN110088101A/en
Publication of WO2018086585A1 publication Critical patent/WO2018086585A1/en
Publication of WO2018086585A8 publication Critical patent/WO2018086585A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Disclosed in the present invention are nitrogen-containing heterocyclic compounds, a preparation method therefor, a pharmaceutical composition thereof, and applications thereof. The nitrogen-containing heterocyclic compounds represented by formula II can be effectively combined with bromodomains of BRD4, BRD3, BRD2 and BRDT of a BET family, and play a specific role.
PCT/CN2017/110438 2016-11-10 2017-11-10 Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof WO2018086585A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780067789.4A CN110088101A (en) 2016-11-10 2017-11-10 A kind of nitrogen-containing hetero cyclics, preparation method, pharmaceutical composition and application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610989839.1 2016-11-10
CN201610989839.1A CN108069959A (en) 2016-11-10 2016-11-10 A kind of nitrogen-containing hetero cyclics, its preparation method, pharmaceutical composition and application

Publications (2)

Publication Number Publication Date
WO2018086585A1 WO2018086585A1 (en) 2018-05-17
WO2018086585A8 true WO2018086585A8 (en) 2018-06-21

Family

ID=62110375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/110438 WO2018086585A1 (en) 2016-11-10 2017-11-10 Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof

Country Status (2)

Country Link
CN (2) CN108069959A (en)
WO (1) WO2018086585A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794477A (en) * 2018-08-06 2018-11-13 华东师范大学 A kind of N2The preparation method of 9 substituted guanine class compound
TW202110818A (en) * 2019-05-24 2021-03-16 美商拜歐斯瑞克斯公司 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
CN112079829B (en) * 2019-06-14 2021-11-26 四川大学 1,2, 4-triazole [4,3-a ] pyridine derivative and preparation method and application thereof
CN110183372B (en) * 2019-06-20 2020-10-30 山东大学 Isatin compound and preparation method and application thereof
CN110272418B (en) * 2019-07-25 2020-10-16 山东大学 Triazole compound and preparation method and application thereof
CN113754541A (en) * 2020-06-02 2021-12-07 深圳湾实验室 Micromolecule inhibitor targeting EB virus nuclear antigen protein, preparation method and application thereof
WO2022033542A1 (en) * 2020-08-14 2022-02-17 南京明德新药研发有限公司 5-membered heteroaromatic pyridone compounds and application thereof
CN112225741B (en) * 2020-12-09 2021-03-30 中山大学 Application of 1,2, 4-triazolo 4,3-B pyridazine derivative in preparation of anti-inflammatory factor storm medicines
CN115028646B (en) * 2022-05-31 2023-06-30 山东第一医科大学(山东省医学科学院) Nitrogen-containing heterocyclic compound, preparation method and application thereof in antitumor preparation
CN115557954B (en) * 2022-11-11 2024-06-11 上海泰坦科技股份有限公司 Preparation method of 6-bromo- [1,2,4] triazolo [4,3-b ] pyridazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014012635A (en) * 2012-04-20 2015-05-15 Abbvie Inc Isoindolone derivatives.
CN105164127A (en) * 2013-03-11 2015-12-16 艾伯维公司 Bromodomain inhibitors
PL3290407T3 (en) * 2013-10-18 2020-09-07 Celgene Quanticel Research, Inc Bromodomain inhibitors
CN105254635A (en) * 2015-10-30 2016-01-20 中国药科大学 Imidazo pyrazine compound, medicine composition of imidazo pyrazine compound and purpose of imidazo pyrazine compound

Also Published As

Publication number Publication date
WO2018086585A1 (en) 2018-05-17
CN108069959A (en) 2018-05-25
CN110088101A (en) 2019-08-02

Similar Documents

Publication Publication Date Title
WO2018086585A8 (en) Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
EP3539963A4 (en) Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
EP3453707A4 (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
EP3494118A4 (en) Nitrogen-containing tricyclic compounds and uses thereof in medicine
WO2018086604A8 (en) Nitrogen-containing heterocyclic compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
NZ611964A (en) Bromodomain inhibitors and uses thereof
CA2903881C (en) Tricyclic heterocycles as bet protein inhibitors
EP3596084A4 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
SG10201809353TA (en) 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
WO2017044792A8 (en) Acetamide thienotriazolodiazepines and uses thereof
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
HK1247203A1 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
WO2016022970A8 (en) Dihydropteridinone derivatives and uses thereof
WO2017044849A8 (en) Cyano thienotriazolodiazepines and uses thereof
EP3498716A4 (en) Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications
EP3421038A4 (en) Naphthyridine compound, pharmaceutical composition and use thereof
EP3424929A4 (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
EP3453393A4 (en) Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same
EP3470415A4 (en) 5-membered heterocycle fused with [3,4-d]pyridazinone, and manufacturing method, pharmaceutical composition, and application thereof
EP3725297A4 (en) Oral pharmaceutical composition containing pemetrexed and production method thereof
IL264511A (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
EP3730492A4 (en) Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869588

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17869588

Country of ref document: EP

Kind code of ref document: A1